GR3031783T3 - 1H-indole-3-acetamide derivatives as sPLA2 inhibitors. - Google Patents

1H-indole-3-acetamide derivatives as sPLA2 inhibitors.

Info

Publication number
GR3031783T3
GR3031783T3 GR990402875T GR990402875T GR3031783T3 GR 3031783 T3 GR3031783 T3 GR 3031783T3 GR 990402875 T GR990402875 T GR 990402875T GR 990402875 T GR990402875 T GR 990402875T GR 3031783 T3 GR3031783 T3 GR 3031783T3
Authority
GR
Greece
Prior art keywords
indole
acetamide derivatives
spla2 inhibitors
spla2
inhibitors
Prior art date
Application number
GR990402875T
Other languages
English (en)
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
Robert Bell Hermann
Richard Walter Schevitz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GR3031783T3 publication Critical patent/GR3031783T3/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GR990402875T 1993-04-16 1999-11-08 1H-indole-3-acetamide derivatives as sPLA2 inhibitors. GR3031783T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4862993A 1993-04-16 1993-04-16
US20872194A 1994-03-15 1994-03-15

Publications (1)

Publication Number Publication Date
GR3031783T3 true GR3031783T3 (en) 2000-02-29

Family

ID=26726342

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402875T GR3031783T3 (en) 1993-04-16 1999-11-08 1H-indole-3-acetamide derivatives as sPLA2 inhibitors.

Country Status (25)

Country Link
US (1) US5684034A (el)
EP (1) EP0620215B1 (el)
JP (1) JPH0725850A (el)
KR (1) KR100317755B1 (el)
CN (1) CN1068588C (el)
AT (1) ATE183503T1 (el)
AU (1) AU676884B2 (el)
BR (1) BR9401482A (el)
CA (1) CA2121323A1 (el)
CO (1) CO4230092A1 (el)
CZ (1) CZ289750B6 (el)
DE (1) DE69420068T2 (el)
DK (1) DK0620215T3 (el)
ES (1) ES2138648T3 (el)
FI (1) FI941767A (el)
GR (1) GR3031783T3 (el)
HU (1) HUT70836A (el)
IL (1) IL109311A0 (el)
NO (1) NO300732B1 (el)
NZ (1) NZ260298A (el)
PL (1) PL181319B1 (el)
RU (1) RU2162463C2 (el)
TW (1) TW268942B (el)
UA (1) UA44218C2 (el)
YU (1) YU20194A (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
US6252084B1 (en) 1994-03-15 2001-06-26 Eli Lilly And Company 1H-indole-3-acetamide sPLA2 inhibitors
CO4370099A1 (es) 1994-04-01 1996-10-07 Lilly Co Eli 1H-INDOL-3-GLIOXILAMIDAS INHIBIDORAS DE sPLA2
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
AU717430B2 (en) * 1996-08-26 2000-03-23 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6713645B1 (en) * 1996-10-30 2004-03-30 Eli Lilly And Company Substituted tricyclics
BR9713261A (pt) * 1996-10-30 2000-03-28 Lilly Co Eli Tricìclicos substituìdos
US6569539B2 (en) 1996-10-30 2003-05-27 Tetra Level Holdings & Finance S.A. Gas barrier packaging laminate method for production thereof and packaging containers
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
CA2279211A1 (en) * 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
SK12752000A3 (sk) * 1998-02-25 2001-03-12 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
ID26123A (id) * 1998-02-25 2000-11-23 Genetics Inst Penghambat-penghambat phospholipase a2
CA2322161A1 (en) * 1998-02-25 1999-09-02 Yibin Xiang Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EP1066290A1 (en) 1998-03-31 2001-01-10 Shionogi & Co., Ltd. PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR
ID23219A (id) * 1998-04-17 2000-03-30 Lilly Co Eli Trisiklik tersubstitusi
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
CN1302300A (zh) 1998-05-21 2001-07-04 盐野义制药株式会社 吡咯并[1,2-b]哒嗪sPLA2抑制剂
DE69931496T2 (de) 1998-08-03 2006-11-23 Eli Lilly And Co., Indianapolis INDOLVERBINDUNGEN ALS sPLA2 INHIBITOREN
JP2002522386A (ja) * 1998-08-03 2002-07-23 イーライ・リリー・アンド・カンパニー インドールsPLA2インヒビター
WO2000010568A1 (en) 1998-08-24 2000-03-02 Draheim Susan E Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase a¿2?
AU6004799A (en) 1998-10-14 2000-05-01 Shionogi & Co., Ltd. Remedies or preventives for ischemic reflow failure
JP2002533345A (ja) 1998-12-22 2002-10-08 イーライ・リリー・アンド・カンパニー 置換三環式化合物
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
WO2001005789A1 (fr) 1999-07-19 2001-01-25 Shionogi & Co., Ltd. Composes tricycliques a action inhibitrice a l'encontre de spla¿2?
JP2003505372A (ja) * 1999-07-19 2003-02-12 イーライ・リリー・アンド・カンパニー sPLA2インヒビター
JP4636522B2 (ja) 1999-08-02 2011-02-23 塩野義製薬株式会社 sPLA2阻害作用を有する三環式化合物
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
DE60032254D1 (de) * 1999-09-20 2007-01-18 Lilly Co Eli Hydroxyfunktionelle amid-1h-indolderivate aktiv als spla2 inhibitoren
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
AU1304801A (en) 1999-11-15 2001-05-30 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an SPLA2- inhibiting effect
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US6608059B1 (en) 2000-06-27 2003-08-19 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2002000256A1 (en) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cirrhosis
US7026318B2 (en) 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
US20050203166A1 (en) * 2000-06-30 2005-09-15 Cancer Research Technology Limited Indole-3-acetic acid derivatives
GB0016162D0 (en) * 2000-06-30 2000-08-23 Cancer Res Campaign Tech Indole-3-acetic acid derivatives
AU2001272915A1 (en) * 2000-07-14 2002-01-30 Eli Lilly And Company Method for treating sepsis
IE20010784A1 (en) * 2000-08-24 2003-04-16 Univ Dublin City N-benzylindole-3-acetic acid derivatives
ATE354567T1 (de) 2000-12-18 2007-03-15 Lilly Co Eli Benz(g)indole und deren verwendung als spla2 inhibitoren
EP1349834A2 (en) * 2000-12-18 2003-10-08 Eli Lilly And Company Cycloalkyfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
TWI314457B (el) * 2001-03-19 2009-09-11 Shionogi & Co
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
US20050032747A1 (en) * 2003-07-01 2005-02-10 Wilmin Bartolini COX-2 and FAAH inhibitors
WO2005037227A2 (en) * 2003-10-16 2005-04-28 Microbia, Inc. Selective cox-2 inhibitors
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US20050234244A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Synthesis of COX-2 and FAAH inhibitors
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
EP1931632A4 (en) * 2005-08-18 2011-05-11 Microbia Inc USEFUL INDOOR CONNECTIONS
WO2007056275A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
CN105384619B (zh) * 2014-08-22 2020-05-29 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2890223A (en) * 1956-03-22 1959-06-09 Research Corp 1-benzyl, 2-methyl, 5-methoxy tryptamine
US3196162A (en) * 1961-03-13 1965-07-20 Merck & Co Inc Indolyl aliphatic acids
US3242162A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3242193A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
US4428962A (en) * 1981-10-30 1984-01-31 Schering Corporation Indoles in treatment of peptic ulcers
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors

Also Published As

Publication number Publication date
CO4230092A1 (es) 1995-10-19
CN1098715A (zh) 1995-02-15
HUT70836A (en) 1995-11-28
NO300732B1 (no) 1997-07-14
ATE183503T1 (de) 1999-09-15
CZ289750B6 (cs) 2002-03-13
UA44218C2 (uk) 2002-02-15
NO941361D0 (no) 1994-04-15
TW268942B (el) 1996-01-21
AU5949294A (en) 1994-10-20
DE69420068T2 (de) 1999-12-23
RU2162463C2 (ru) 2001-01-27
BR9401482A (pt) 1994-10-18
US5684034A (en) 1997-11-04
NZ260298A (en) 1996-05-28
FI941767A0 (fi) 1994-04-15
CA2121323A1 (en) 1994-10-17
AU676884B2 (en) 1997-03-27
DK0620215T3 (da) 1999-12-06
FI941767A (fi) 1994-10-17
DE69420068D1 (de) 1999-09-23
ES2138648T3 (es) 2000-01-16
CN1068588C (zh) 2001-07-18
EP0620215A1 (en) 1994-10-19
JPH0725850A (ja) 1995-01-27
NO941361L (no) 1994-10-17
YU20194A (sh) 1997-09-30
KR100317755B1 (ko) 2002-08-09
CZ89394A3 (en) 1994-12-15
PL181319B1 (pl) 2001-07-31
HU9401060D0 (en) 1994-07-28
IL109311A0 (en) 1994-07-31
EP0620215B1 (en) 1999-08-18

Similar Documents

Publication Publication Date Title
GR3031783T3 (en) 1H-indole-3-acetamide derivatives as sPLA2 inhibitors.
AU669782B2 (en) 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors
AU1621795A (en) 1H-indole-3-glyoxylamide sPLA2 inhibitors
AU1289797A (en) Naphthyl acetamides as spla2 inhibitors